Comparative Pharmacology
Head-to-head clinical analysis: NITROMIST versus RECTIV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NITROMIST versus RECTIV.
NITROMIST vs RECTIV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nitroglycerin is a prodrug that releases nitric oxide (NO) which activates guanylyl cyclase, increasing cGMP in smooth muscle cells, leading to vasodilation primarily of venous capacitance vessels and coronary arteries.
RECTIV (nitroglycerin) is a nitric oxide (NO) donor that relaxes vascular smooth muscle via stimulation of intracellular cyclic guanosine monophosphate (cGMP) production, leading to vasodilation. In chronic anal fissures, it reduces internal anal sphincter pressure and improves blood flow to the anoderm.
1-2 sprays (0.4-0.8 mg) sublingually or intraorally at onset of angina, may repeat every 5 minutes up to 3 doses. Prophylaxis: 1 spray (0.4 mg) 5-10 minutes before activity.
1 gram (0.5 mg nitroglycerin) applied intrarectally as an ointment 10-15 minutes before anticipated bowel movement, up to twice daily.
None Documented
None Documented
2–3 minutes for nitroglycerin; rapid metabolism results in short terminal half-life. Clinically, effects dissipate within 30 minutes of discontinuation.
Terminal elimination half-life is approximately 2-4 hours in healthy adults. In patients with severe hepatic impairment, half-life may be prolonged up to 8-10 hours, requiring dose adjustment.
Renal excretion of inactive metabolites accounts for >80% of elimination; biliary/fecal excretion is minimal (<15%).
Primarily renal; approximately 60-70% of the parent drug and metabolites excreted in urine within 24 hours. Fecal elimination accounts for ~20-30% via biliary secretion. Less than 1% unchanged drug recovered in feces.
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator